BrainStorm Cell director awarded 100,000 RSUs

FRENKEL JACOB A reported acquisition or exercise transactions in this Form 4 filing.

Accepted by SEC EDGAR 07/28/2026 - 05:01 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

FRENKEL JACOB A reported acquisition or exercise transactions in this Form 4 filing.

BrainStorm Cell Therapeutics Inc. reported that director Jacob A. Frenkel received a grant of 100,000 restricted stock units (RSUs) representing common stock under a Consulting Agreement dated July 24, 2026 and the 2014 Global Share Option Plan. The RSUs vest 50% on October 24, 2026 and 50% on April 24, 2027, contingent on continued service. Following this equity award, his direct holdings are reported at 343,777 shares of common stock.

Insider Trade Summary

Grant/Award: 100,000 shares

Grant/Award 1 txn

Insider FRENKEL JACOB A

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock F1	100,000	$0.00	$0.00

Holdings After Transaction: Common Stock — 343,777 shares (Direct)

Holdings Before and After: Common Stock, 243,777 to 343,777 shares (Direct)

Footnotes (1)

1. F1. Represents shares of restricted stock units ("RSUs") issued pursuant to a Consulting Agreement dated July 24, 2026 between the Reporting Person and the Issuer (the "Consulting Agreement") and subject to the 2014 Global Share Option Plan. The RSUs shall vest as to (i) 50% of the award on October 24, 2026, and (ii) the remaining 50% of the award on April 24, 2027, provided that the Reporting Person continues to provide services to the Issuer pursuant to the Consulting Agreement through each applicable vesting date.

Key Figures

RSUs granted: 100,000 shares Holdings after grant: 343,777 shares First vesting portion: 50% of RSUs +2 more

5 metrics

RSUs granted 100,000 shares Restricted stock units granted on July 24, 2026 under a Consulting Agreement

Holdings after grant 343,777 shares Total direct common stock holdings reported following the RSU award

First vesting portion 50% of RSUs Vests on October 24, 2026, subject to continued service

Second vesting portion 50% of RSUs Vests on April 24, 2027, subject to continued service

Consulting Agreement date July 24, 2026 Agreement between Jacob A. Frenkel and the issuer governing the RSU grant

Key Terms

restricted stock units, 2014 Global Share Option Plan, Consulting Agreement

3 terms

restricted stock units financial

"Represents shares of restricted stock units RSUs issued pursuant to a Consulting"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

2014 Global Share Option Plan financial

"subject to the 2014 Global Share Option Plan. The RSUs shall vest"

Consulting Agreement financial

"issued pursuant to a Consulting Agreement dated July 24, 2026 between the Reporting"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did BCLI disclose for Jacob A. Frenkel?

BRAINSTORM CELL THERAPEUTICS INC. disclosed that director Jacob A. Frenkel was granted 100,000 RSUs representing common stock. The award was issued under a Consulting Agreement dated July 24, 2026 and the company’s 2014 Global Share Option Plan as equity compensation.

How many RSUs did Jacob A. Frenkel receive from BCLI and when do they vest?

Jacob A. Frenkel received 100,000 RSUs from BCLI. The RSUs vest in two equal tranches: 50% of the award on October 24, 2026 and the remaining 50% on April 24, 2027, subject to his continued service under the Consulting Agreement.

What are Jacob A. Frenkel’s total reported BCLI holdings after this RSU grant?

After the reported RSU grant, Jacob A. Frenkel’s direct holdings are listed at 343,777 shares of BCLI common stock. This figure reflects his total direct position immediately following the 100,000 RSU award described in the Form 4 filing.

What agreement governs the RSU grant reported by BCLI for Jacob A. Frenkel?

The RSU grant to Jacob A. Frenkel is governed by a Consulting Agreement dated July 24, 2026 between him and BCLI. The award is also subject to the company’s 2014 Global Share Option Plan, which sets the equity compensation framework and conditions.

Is the BCLI Form 4 transaction a market purchase or sale of stock?

No, the reported transaction is a grant of 100,000 RSUs, not an open-market purchase or sale of BCLI shares. It represents equity compensation that will convert into common stock as the RSUs vest on specified future dates, assuming continued service.

What service condition applies to Jacob A. Frenkel’s BCLI RSU vesting?

Vesting of Jacob A. Frenkel’s RSUs requires that he continues to provide services to BCLI under the Consulting Agreement through each vesting date. If service continues, 50% vests on October 24, 2026 and 50% vests on April 24, 2027.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

X

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

FRENKEL JACOB A

(Last) (First) (Middle)

C/O BRAINSTORM CELL THERAPEUTICS INC.

1325 AVENUE OF THE AMERICAS 28TH FLOOR

(Street)

NEW YORK NEW YORK 10019

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BRAINSTORM CELL THERAPEUTICS INC. [ BCLI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/24/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/24/2026		A		100,000(1)	A	$0.00	343,777	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares of restricted stock units ("RSUs") issued pursuant to a Consulting Agreement dated July 24, 2026 between the Reporting Person and the Issuer (the "Consulting Agreement") and subject to the 2014 Global Share Option Plan. The RSUs shall vest as to (i) 50% of the award on October 24, 2026, and (ii) the remaining 50% of the award on April 24, 2027, provided that the Reporting Person continues to provide services to the Issuer pursuant to the Consulting Agreement through each applicable vesting date.

	/s/ Jacob A. Frenkel	07/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)